Dr Christopher B. Cooper
Dr Christopher B. (Chris) Cooper currently serves as Senior Director, Chemistry, at TB Alliance. After receiving his Ph.D. from Stanford University in 1988, Dr Cooper spent over ten years engaged in medicinal chemistry research at Pfizer, Inc. in both the US and UK.
In 1998, Chris joined Bristol-Myers Squibb, Inc. (BMS) to launch the Lead Synthesis Group spearheading the design and synthesis of drug-like medicinal chemistry arrays. Dr Cooper’s team was responsible for the pharmacological assessment of exploratory biological targets, and the advancement of early- and full-phase discovery programs.
Dr Cooper joined TB Alliance in 2009 where he oversees the Alliance’s global discovery and preclinical development chemistry activities. Chris has published over 70 peer-reviewed papers, and is co-inventor on over two dozen U.S. and PCT patents.